Robert L Hickok And Gay Parks Rainville

January 04, 2012 | The Legal Intelligencer

Last March, in the securities class action Matrixx Initiatives v. Siracusano, the U.S. Supreme Court unanimously rejected the defendants' proposed bright-line "statistically significant" rule for determining whether adverse event reports withheld from a pharmaceutical company's public filings are material as a matter of law.

By Robert L. Hickok and Gay Parks Rainville

11 minute read

June 04, 2013 | The Legal Intelligencer

The third proxy season of the Dodd-Frank Act's mandatory shareholder "say-on-pay" advisory votes is well underway, and "round two" of shareholder say-on-pay litigation is in full swing.

By Robert L. Hickok and Gay Parks Rainville

10 minute read

July 17, 2012 | The Legal Intelligencer

On June 11, the U.S. Supreme Court agreed to hear biotechnology company Amgen Inc.'s appeal of the U.S. Court of Appeals for the Ninth Circuit's decision to affirm class certification in the securities fraud class action Amgen v. Connecticut Retirement Plans and Trust Funds.

By Robert L. Hickok And Gay Parks Rainville

9 minute read

March 24, 2009 | The Legal Intelligencer

The 3rd U.S. Circuit Court of Appeals' recent decisions in In re Merck & Co. Inc. Securities, Derivative & ERISA Litigation and Alaska Electrical Pension Fund v. Pharmacia Corp., illustrate an unintended consequence of the Private Securities Litigation Reform Act's, or PSLRA, heightened pleading requirements: an increase in the defendant's burden to show that a plaintiff's federal securities fraud claim is time

By Robert L. Hickok And Gay Parks Rainville

10 minute read